Home | Careers | BI | Contact us

Sativex® receives regulatory approval in Israel

June 13, 2012

Neopharm Group and GW Pharmaceuticals plc announced that Sativex┬« (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray) has received regulatory approval from the Israeli Ministry of Health for the treatment of spasticity and neuropathic pain due…

logo Maala

Neopharm Receives Platinum Ratings in Maala CSR Index for 2012

Neopharm Group is proud to announce that it has received platinum ratings for its CSR (Corporate Social Responsibility) activities from Maala CSR Index, which is an index rating companies in CSR since 2003. The ratings…

Environmental Policy

April 5, 2012

Neopharm Group considers environmental conservation an integral part of its everyday business decisions. The group is aware of the impact its activities have on the environment. We set our goal on developing equilibrium between business…

Health and Safety in Workplace Policy

March 20, 2012

Neopharm Group’s management is committed to providing its employees, guests and service providers who enter the group facilities, a safe and healthy work environment. To fulfill this commitment, all of the group’s managers and employees…

Home | About Us | Companies | Partnering | Research | Corporate Citizenship | Careers | Newsroom | Contact | Legal Notice

All Rights reserved, Neopharm Group, Israel | Design by: VAZA | Developed by: The Shark Lady